Cargando…

Bivalent Vaccine Effectiveness Among Adults Aged ≥65 Years During the BA.5-Predominant Period in Japan: The VENUS Study

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron BA.5 became prevalent in July 2022 in Japan. Bivalent messenger RNA (mRNA) vaccines were approved as booster doses for individuals who received the primary series or booster dose by monovalent vaccines. We aimed to asse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mimura, Wataru, Ishiguro, Chieko, Terada-Hirashima, Junko, Matsunaga, Nobuaki, Maeda, Megumi, Murata, Fumiko, Fukuda, Haruhisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10588616/ https://www.ncbi.nlm.nih.gov/pubmed/37869405 http://dx.doi.org/10.1093/ofid/ofad475

Ejemplares similares

Effectiveness of a Third Dose of COVID-19 mRNA Vaccine During the Omicron BA.1- and BA.2-Predominant Periods in Japan: The VENUS Study
por: Mimura, Wataru, et al.
Publicado: (2022)

Multiregional Population-Based Cohort Study for Evaluation of the Association Between Herpes Zoster and mRNA Vaccinations for Severe Acute Respiratory Syndrome Coronavirus-2: The VENUS Study
por: Ishiguro, Chieko, et al.
Publicado: (2023)

Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study
por: Mimura, Wataru, et al.
Publicado: (2022)

Development of a COVID-19 vaccine effectiveness and safety assessment system in Japan: The VENUS study
por: Fukuda, Haruhisa, et al.
Publicado: (2023)

Effect of COVID-19 Vaccination on Household Transmission of SARS-CoV-2 in the Omicron Era: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study
por: Maeda, Megumi, et al.
Publicado: (2023)

Acute and delayed psychiatric sequelae among patients hospitalised with COVID-19: a cohort study using LIFE study data
por: Murata, Fumiko, et al.
Publicado: (2022)

Association between seasonal influenza vaccination and antimicrobial use in Japan from the 2015–16 to 2020–21 seasons: from the VENUS study
por: Tsuzuki, Shinya, et al.
Publicado: (2023)

Omicron Variant-Specific Serological Imprinting Following BA.1 or BA.4/5 Bivalent Vaccination and Previous SARS-CoV-2 Infection: A Cohort Study
por: Baerends, Eva A M, et al.
Publicado: (2023)

Anti-Dementia Drug Persistence Following Donepezil Initiation Among Alzheimer’s Disease Patients in Japan: LIFE Study
por: Fukuda, Haruhisa, et al.
Publicado: (2022)

Protection of COVID-19 Vaccination Against Hospitalization During the Era of Omicron BA.4 and BA.5 Predominance: A Nationwide Case–Control Study Based on the French National Health Data System
por: Semenzato, Laura, et al.
Publicado: (2023)

Medical Care and Long-Term Care Expenditures Attributable to Alzheimer’s Disease Onset: Results from the LIFE Study
por: Fukuda, Haruhisa, et al.
Publicado: (2021)

Disease Burden and Progression in Patients with New-Onset Mild Cognitive Impairment and Alzheimer’s Disease Identified from Japanese Claims Data: Evidence from the LIFE Study
por: Fukuda, Haruhisa, et al.
Publicado: (2023)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants
por: Jäger, Michael, et al.
Publicado: (2023)

Trends in Cases, Hospitalizations, and Mortality Related to the Omicron BA.4/BA.5 Subvariants in South Africa
por: Jassat, Waasila, et al.
Publicado: (2022)

The Longevity Improvement & Fair Evidence (LIFE) Study: Overview of the Study Design and Baseline Participant Profile
por: Fukuda, Haruhisa, et al.
Publicado: (2023)

Predicting the Public Health Impact of Bivalent Vaccines and Nirmatrelvir-Ritonavir Against Coronavirus Disease 2019
por: Park, Hailey J, et al.
Publicado: (2023)

Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children
por: Tagbo, Beckie N, et al.
Publicado: (2020)

Antimicrobial utilization and antimicrobial resistance in patients with haematological malignancies in Japan: a multi-centre cross-sectional study
por: Mimura, Wataru, et al.
Publicado: (2020)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

Antibody Binding and Angiotensin-Converting Enzyme 2 Binding Inhibition Is Significantly Reduced for Both the BA.1 and BA.2 Omicron Variants
por: Junker, Daniel, et al.
Publicado: (2022)

Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
por: Kopel, Hagit, et al.
Publicado: (2023)

Delineating the Spread and Prevalence of SARS-CoV-2 Omicron Sublineages (BA.1–BA.5) and Deltacron Using Wastewater in the Western Cape, South Africa( )
por: Johnson, Rabia, et al.
Publicado: (2022)

Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type–Specific Effectiveness and Evidence of Cross-Protection
por: Kudo, Risa, et al.
Publicado: (2019)

Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine
por: Zou, Jing, et al.
Publicado: (2023)

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022)

Is a booster dose of COVID-19 vaccines effective on newly dominant omicron subvariants among university students? Comparison between BA.1 and BA.2 dominancy
por: Miyauchi, Shunsuke, et al.
Publicado: (2022)

Brève : Avis positif pour l’UE du rappel bivalent Omicron BA.4/BA.5
por: Dalmat, Yann-Mickael
Publicado: (2022)

Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study
por: Andersson, Niklas Worm, et al.
Publicado: (2023)

Reduced Pathogenicity and Transmission Potential of Omicron BA.1 and BA.2 Sublineages Compared with the Early Severe Acute Respiratory Syndrome Coronavirus 2 D614G Variant in Syrian Hamsters
por: Su, Wen, et al.
Publicado: (2022)

Primary Series and Booster Coronavirus Disease 2019 Vaccine Effectiveness in a Cohort of Healthcare Workers in Albania During a BA.1 and BA.2 Variant Period, January–May 2022
por: Finci, Iris, et al.
Publicado: (2023)

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
por: Springer, David N., et al.
Publicado: (2023)

Venus observada /
por: Fry, Christopher, 1907-2005
Publicado: (1955)

Venus aeronomy
por: Russell, C
Publicado: (1991)

Mercury and venus
por: World Book
Publicado: (2013)

Venus or Æsculapius?
Publicado: (1888)

Low WSS and High OSI Measured by 3D Cine PC MRI Reflect High Pulmonary Artery Pressures in Suspected Secondary Pulmonary Arterial Hypertension
por: TERADA, Masaki, et al.
Publicado: (2015)

Prevalence and determinants of depressive symptoms in patients with Chagas cardiomyopathy and predominantly preserved cardiac function
por: Silva, Whesley Tanor, et al.
Publicado: (2020)

Immunogenicity of Bivalent Omicron BA.4/5–Adapted Vaccine in Hemodialysis Patients
por: Anft, Moritz, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5d8of3o37mbn7hrr5eu97c2pl1